2-Propanol: Clinical Trials

11 trials of 2-Propanol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 3 completed, 2 not yet recruiting, 1 recruiting. 11 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Active not recruiting 3, Completed 3, Not yet recruiting 2, Recruiting 1, Suspended 1, Terminated 1
Phase 11Suspended 1

Follow 2-Propanol: new trials by email Literature Review of 2-Propanol trials Research Report on 2-Propanol

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer
Isopropyl Alcohol, Placebo, Questionnaire Administration - Malignant Neoplasm
Phase 2Not yet recruitingM.D. Anderson Cancer Center1122026-11-052026-05-27
Propranolol Treatment for Postoperative Chylothorax
Propranolol Hydrochloride, Placebo - Postoperative Chylothorax, Congenital Heart Disease
Phase 1 / Phase 2SuspendedJune Wu502025-09-092026-05-15
Cleaning the Biopsy Needle in TRUS Bx
Isopropyl Alcohol, Povidine-iodine, formaldehit - Prostatic Cancer
Phase 2Not yet recruitingHitit University2002025-03-012025-02-20
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 2Active not recruitingChildren's Oncology Group12023-08-142026-01-09
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
Enasidenib Mesylate - Acute Myeloid Leukemia
Phase 2Active not recruitingCity of Hope Medical Center352019-12-232026-11-10
CPX-351 Plus Enasidenib for Relapsed AML
Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine - Recurrent Acute Myeloid Leukemia
Phase 2Active not recruitingJonsson Comprehensive Cancer Center22019-04-122023-09-28
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Azacitidine, Enasidenib Mesylate - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia
Phase 2RecruitingM.D. Anderson Cancer Center502018-09-182026-09-14
In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area
3M CHG/IPA Prep - Surgical Skin Preparation, Surgical Procedure, Unspecified
Phase 2CompletedSolventum US LLC282017-06-062024-10-02
In Vivo Preoperative Skin Preparation Persistence Evaluation
3M CHG/IPA Prep, ChloraPrep - Bacterial Recovery of Skin Flora Post-product Application
Phase 2CompletedSolventum US LLC692016-12-052024-10-02
Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™
Chloraprep, ZuraPrep, ZuraPrep Vehicle - Surgical Site Infection
Phase 2TerminatedZurex Pharma, Inc.642014-08-012016-07-18
Efficacy of JUC as Hand Rub Evaluated by Using European Standard 1500
JUC solution, propan-2-ol - Infectious Disease Transmission
Phase 2CompletedThe Hong Kong Polytechnic University152012-06-012014-12-11

Conditions studied

Leukemia, Myeloid, Acute (4)  ·  Chylothorax (1)  ·  Heart Defects, Congenital (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Sepsis (1)  ·  Surgical Wound Infection (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  Solventum US LLC (2)  ·  Children's Oncology Group (1)  ·  City of Hope Medical Center (1)  ·  Hitit University (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  June Wu (1)  ·  The Hong Kong Polytechnic University (1)  ·  Zurex Pharma, Inc. (1)

Countries

United States (7)  ·  Canada (1)  ·  Hong Kong (1)  ·  Romania (1)

Top investigators

Rozalia Olsavszky, MD (2)  ·  Amandeep Salhotra (1)  ·  Caspian Oliai, MD (1)  ·  Chris Beausoleil (1)  ·  Courtney DiNardo (1)  ·  John Yuen, PhD (1)  ·  June Wu, MD (1)  ·  Sara Zarnegar-Lumley (1)  ·  Yvonne J Heung (1)

Results publications

PMID 33394722, PMID 35078972, PMID 42369177

NIH funding

U10CA180886 (1)